The use of sodium oxybate to treat narcolepsy

  title={The use of sodium oxybate to treat narcolepsy},
  author={Geert Mayer},
  journal={Expert Review of Neurotherapeutics},
  pages={519 - 529}
  • G. Mayer
  • Published 1 May 2012
  • Psychology, Medicine
  • Expert Review of Neurotherapeutics
Narcolepsy is a life-long neurodegenerative disorder that causes considerable impairment to quality of life. Until the 1970s, the treatment for one of the main symptoms, excessive daytime sleepiness, was restricted to stimulants, whereas the second core symptom, cataplexy, was treated with antidepressants, and the resultant fragmented night-time sleep with hypnotics. Sodium oxybate (Xyrem®, UCB Pharma, Brussels, Belgium) is an efficacious drug for all three symptoms which improves the quality… 

Clinical applications of sodium oxybate (GHB): from narcolepsy to alcohol withdrawal syndrome.

The effectiveness of sodium oxybate therapy for the treatment of alcohol withdrawal syndrome (AWS) and the maintenance of alcohol abstinence has been assessed and some randomized data suggest that GHB is better than naltrexone and disulfiram regarding abstinence maintenance and prevention of craving in the medium term i.e. 3-12 months.

Treatment options in narcolepsy

The choice of stimulants to treat excessive daytime sleepiness in narcolepsy needs to be expanded and anticataplectic medication need to be approved for the indication.

GHB for cataplexy: Possible mode of action

  • E. Szabadi
  • Biology
    Journal of psychopharmacology
  • 2015
GHB may prevent a cataplectic attack by dampening the tone of LC neurones via the stimulation of inhibitory extrasynaptic GABA receptors in the LC, and thus increasing the threshold for autoinhibition.

Increased lucid dreaming frequency in narcolepsy.

Narcolepsy patients experience a markedly higher lucid dreaming frequency compared to controls, and many patients report a positive impact of dream lucidity on the distress experienced from nightmares.

DARK Classics in Chemical Neuroscience: Gamma-hydroxybutyrate (GHB).

GHB has a storied history with widespread usage in therapeutic, recreational, recreational ('Chemsex'), and some disturbingly nefarious contexts, and a recent surge in therapeutic interest in the drug due to its clinical viability in the treatment of narcolepsy and alcohol abuse/withdrawal.

Post-marketing and clinical safety experience with sodium oxybate for the treatment of alcohol withdrawal syndrome and maintenance of abstinence in alcohol-dependent subjects

The cumulative postmarketing and clinical safety experience with SMO in AUD showed that SMO has a good safety profile in AUD patients, and the safety profile was confirmed by pharmacovigilance data resulting from 299 013 patients exposed from Italy and Italy.

Understanding narcolepsy: the wider perspective

Recent evidence of importance to understanding narcolepsy and managing its effects on health-related quality of life is examined.

Recent strategies for drug development in fibromyalgia syndrome

The results of these studies with potential novel targets for drug development for FMS were reviewed including the results of trials with sodium oxybate, quetiapine, esreboxetine, nabilone, memantine, naltrexone, and melatonin.



EFNS guidelines on management of narcolepsy

A task force composed of the leading specialists of narcolepsy in Europe conducted an extensive review of pharmacological and behavioral trials available in the literature to reinforce the use of those drugs evaluated in randomized placebo‐controlled trials and to reach a consensus, as much as possible, on theUse of other available medications.

Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin.

These practice parameters serve as both an update of previous practice parameters for the therapy of narcolepsy and as the first practice parameters to address treatment of other hypersomnias of central origin, based on evidence analyzed in the accompanying review paper.

Sodium oxybate: neurobiology and clinical efficacy

Sodium oxybate is indicated for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy, and has been shown to improve disrupted night-time sleep and increase Stage 3 and 4 (slow-wave restorative) sleep in this patient population.

Clinical perspective: monitoring sodium oxybate-treated narcolepsy patients for the development of sleep-disordered breathing

Among narcolepsy patients with evidence of sleep disordered breathing during baseline polysomnography, SXB should be prescribed only to those patients who fully comply with nasal continuous positive airway pressure therapy, and the respiratory status of SXB-treated patients should be periodically evaluated with nocturnal oximetry.

Pharmacokinetics of gammahydroxybutyrate (GHB) in narcoleptic patients.

The data confirm that GHB treatment decreases daytime sleepiness and episodes of cataplexy, sleep paralysis, and hypnagogic hallucinations, and GHB elimination appears to be capacity-limited in some patients when administered at a fixed dose of 3 g twice nightly at a 4-hour interval.

A randomized trial evaluating the effectiveness of sodium oxybate therapy on quality of life in narcolepsy.

The nightly administration of sodium oxybate produced significant dose-related improvements in the Total Functional Outcomes of Sleep Questionnaire score, as well as in the Activity Level, General Productivity, Vigilance, and Social Outcomes subscales.

Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam.

  • K. AndersonJ. Shneerson
  • Medicine, Psychology
    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
  • 2009
Several novel and effective therapies are reported in a series of patients under long-term follow-up for RBD, in particular zopiclone, which can be as effective and may be better tolerated as clonazepam.

The effects of gamma-hydroxybutyrate on sleep.

It is suggested that GHB may serve as the prototype for a new class of hypnotic compounds derived from natural sources and capable of activating the neurological mechanisms of normal human sleep.

Catathrenia under sodium oxybate in narcolepsy with cataplexy

Catathrenia should be considered a possible side effect in NC patients under SO treatment and should be accurately identified to prevent unnecessary SO withdrawal.